PMID- 30755503
OWN - NLM
STAT- MEDLINE
DCOM- 20200721
LR  - 20231013
IS  - 1549-490X (Electronic)
IS  - 1083-7159 (Print)
IS  - 1083-7159 (Linking)
VI  - 24
IP  - 9
DP  - 2019 Sep
TI  - Can Peripherally Inserted Central Catheters Be Safely Placed in Patients with 
      Cancer Receiving Chemotherapy? A Retrospective Study of Almost 400,000 
      Catheter-Days.
PG  - e953-e959
LID - 10.1634/theoncologist.2018-0281 [doi]
AB  - BACKGROUND: Peripherally inserted central catheters (PICCs) are central venous 
      catheters (CVCs) that are commonly used in onco-hematologic settings for 
      chemotherapy administration. As there is insufficient evidence to recommend a 
      specific CVC for chemotherapy administration, we aimed to ascertain PICC-related 
      adverse events (AEs) and identify independent predictors of PICC removal in 
      patients with cancer receiving chemotherapy. MATERIALS AND METHODS: Information 
      on adult patients with cancer with a PICC inserted for chemotherapy 
      administration between September 2007 and December 2014 was extracted from six 
      hospital databases. The primary outcome was PICC removal due to PICC-related AEs 
      (occlusion, infection, or symptomatic thrombosis). Independent predictors of PICC 
      removal were identified using a multivariate Cox regression model. RESULTS: Among 
      the 2,477 included patients, 419 PICC-related AEs (16.9%; 1.09 AEs per 1,000 
      PICC-days) were reported. AEs increased when PICC was inserted at the brachial 
      site (hazard ratio [HR], 1.37; 95% confidence interval [CI], 1.02-1.84) and with 
      open systems (HR, 1.89; 95% CI, 1.24-2.88) and decreased in older men (HR, 0.63; 
      95% CI, 0.49-0.81). CONCLUSION: Use of PICC for chemotherapy administration was 
      associated with a low all-AEs rate. The basilic vein was the safer site, and 
      valved systems had fewer AEs than open systems. More research is needed to 
      explore the interaction between AEs, sex, and age. IMPLICATIONS FOR PRACTICE: 
      These findings provide clinicians with evidence that peripherally inserted 
      central catheters (PICCs) are safe for chemotherapy administration. They also 
      suggest that clinicians should limit the use of open systems when long 
      chemotherapy regimens are scheduled. Moreover, alternatives to PICCs should be 
      considered when administering chemotherapy to young men.
CI  - (c) AlphaMed Press 2019.
FAU - Campagna, Sara
AU  - Campagna S
AD  - Department of Public Health and Pediatrics, University of Torino, Torino, Italy.
FAU - Gonella, Silvia
AU  - Gonella S
AD  - Azienda Ospedaliero Universitaria Citta della Salute e della Scienza di Torino, 
      Torino, Italy silvia.gonella@unito.it.
FAU - Berchialla, Paola
AU  - Berchialla P
AD  - Department of Clinical and Biological Sciences, University of Torino, Torino, 
      Italy.
FAU - Morano, Giacomo
AU  - Morano G
AD  - Azienda Policlinico Umberto I, Rome, Italy.
FAU - Rigo, Carla
AU  - Rigo C
AD  - Azienda Ospedaliero Universitaria Maggiore della Carita, Novara, Italy.
FAU - Zerla, Pietro Antonio
AU  - Zerla PA
AD  - Azienda Socio Sanitaria Territoriale Melegnano e della Martesana, Vizzolo 
      Predabissi, Italy.
FAU - Fuzzi, Raffaella
AU  - Fuzzi R
AD  - Azienda Unita Sanitaria Locale Romagna sede di Forli, Forli, Italy.
FAU - Corona, Gianvito
AU  - Corona G
AD  - Azienda Sanitaria Provinciale Potenza, Potenza, Italy.
FAU - Storto, Silvana
AU  - Storto S
AD  - Azienda Policlinico Umberto I, Rome, Italy.
FAU - Dimonte, Valerio
AU  - Dimonte V
AD  - Department of Public Health and Pediatrics, University of Torino, Torino, Italy.
AD  - Azienda Ospedaliero Universitaria Citta della Salute e della Scienza di Torino, 
      Torino, Italy.
FAU - Mussa, Baudolino
AU  - Mussa B
AD  - Azienda Ospedaliero Universitaria Citta della Salute e della Scienza di Torino, 
      Torino, Italy.
LA  - eng
PT  - Journal Article
DEP - 20190212
PL  - England
TA  - Oncologist
JT  - The oncologist
JID - 9607837
SB  - IM
MH  - Aged
MH  - Catheterization, Peripheral/*adverse effects
MH  - Central Venous Catheters/*adverse effects
MH  - Drug Therapy
MH  - Drug-Related Side Effects and Adverse Reactions/drug therapy/pathology
MH  - Female
MH  - Hematologic Neoplasms/complications/*drug therapy/epidemiology/pathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Thrombosis/epidemiology/etiology/*pathology
PMC - PMC6738314
OTO - NOTNLM
OT  - Complications
OT  - Hematologic neoplasms
OT  - Medical oncology
OT  - Patient safety
OT  - Peripheral catheterization
OT  - Vascular access devices
COIS- Disclosures of potential conflicts of interest may be found at the end of this 
      article.
EDAT- 2019/02/14 06:00
MHDA- 2020/07/22 06:00
PMCR- 2019/09/01
CRDT- 2019/02/14 06:00
PHST- 2018/05/09 00:00 [received]
PHST- 2018/11/21 00:00 [accepted]
PHST- 2019/02/14 06:00 [pubmed]
PHST- 2020/07/22 06:00 [medline]
PHST- 2019/02/14 06:00 [entrez]
PHST- 2019/09/01 00:00 [pmc-release]
AID - theoncologist.2018-0281 [pii]
AID - ONCO12844 [pii]
AID - 10.1634/theoncologist.2018-0281 [doi]
PST - ppublish
SO  - Oncologist. 2019 Sep;24(9):e953-e959. doi: 10.1634/theoncologist.2018-0281. Epub 
      2019 Feb 12.